Company intelligence / Profile preview
LUNAC Therapeutics
Leeds, England, United Kingdomlunactherapeutics.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
01
Overview
LUNAC Therapeutics is a University of Leeds spin-out developing first‑in‑class small‑molecule oral and intravenous FXIIa inhibitors as next‑generation anticoagulants aimed at preventing pathological thrombosis while minimizing bleeding risk; programs are currently in discovery/early preclinical development with no published clinical trial results yet.
- Therapeutic areas
- HematologyCardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on LUNAC Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LUNAC Therapeutics.